Chemotherapy response

DNA Repair and Mitotic Checkpoint Genes as Potential Predictors of Chemotherapy Response in Non-Small-Cell Lung Cancer... 

Based on transcriptional profiling, Oncotype DX and MammaPrint, which will be described in details later in this section, have been developed and used in clinics. It has been shown that the gene expression-based microarray profiling offers tremendous potential to define subcategories of breast cancer, to predict disease relapse, to predict chemotherapy response, and to predict progression of ductal carcinoma in situ (7). 

Iba T, Kigawa J, Kanamori Y, et al. Expression of the c-myc gene as a predictor of chemotherapy response and a prognostic factor in patients with ovarian cancer. Cancer Sci 2004 95(5) 418-423. 

Griffiths-Jones, S. et al. 2008. miRBase tools for microRNA genomics. Nucleic Acids Res. 36, D154—158. Hannon, G.J. et al. 2008. Topoisomerase levels determine chemotherapy response in vitro and in vivo, http // www.pnas.org/content/105/26/9053.full.pdf. Accessed Oct. 2009. 

Bogden AE, Cobb WR, Lepage DJ et al. Chemotherapy responsiveness of human tumors as first transplant generation xenografts in the normal mouse Six-day subrenal capsule assay. Cancer 1981 48 10-20. 

Gallo G, Giarnieri E, Bosco S, et al. Aberrant bcl-2 and bax protein expression related to chemotherapy response in neuroblastoma. Anticancer Res. 2003 23 777-784. 

From Parratt and West , by courtesy of British Journa/ of Pharmacology and Chemotherapy) Responses measured in terms of the maximal values (too per cent) found in saline-treated rats. 

Yeh JJ, Hsu NY, Hsu WH, Tsai CH, Lin CC and Liang JA. Comparison of chemotherapy response with P-glycoprotein, multidrug resistance-related protein-1, and lung resistance-related protein expression in untreated small cell lung cancer. Ltmg 2005 183 177-183. 

Yeh JJ, Hsu WH, Wang JJ, Ho ST and Kao A. Predicting chemotherapy response to pacUtaxel-based therapy in advanced non-small-cell lung cancer with P-glycoprotein expression. Respiration 2003 70 32-35. 

Liang JA, Shiau YC, Yang SN, Lin FJ, Lin CC, Kao A et al. Using technetium-99m-tetrofosmin scan to predict chemotherapy response of malignant lymphomas, compared with P-glycoprotein and multidrug resistance related protein expression. Oncol Rep 2002 9 307-312. 

Shiau YC, Tsai SC, Wang JJ, Ho YJ, Ho ST and Kao CH. To predict chemotherapy response using technetium-99m tetrofosmin and compare with p-glycoprotein and multidrug resistance related protein-1 expression in patients with untreated small cell lung cancer. Cancer Lett 2001 169 181 188. 

Hsueh WA, Kesner AL, Gangloff A, Pegram MD, Beryt M, Czernin J et al. Predicting chemotherapy response to paclitaxel with 18F-Fluoropaclitaxel and PET. J Nucl Med 2006 47 1995-1999. 

Shani J and Wolf W. A model for prediction of chemotherapy response to 5-fluorouracil based on the differential distribution of 5-[18F]fluorouracil in sensitive versus resistant lymphocytic leukemia in mice. Cancer Res 1977 37 2306-2308. 

Ugurel, S., Houben, R., Schrama, D., Voigt, H., Zapatka, M., Schadendotf, D., Brocker, E.B., and Becker, J.C. (2007). Microphthalmia-associated transcription factor gene anplification in metastatic melanoma is a prognostic marker for patient survival, but not a predictive marker for chemosensitivity and chemotherapy response. Clin. Cancer Res. 13, 6344—6350. 

---